.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In August 2026, Stigma Grow concentrated 70.88% of sales in Concentrates with a 6.32% month-over-month lift but a 6.34% year-over-year decline, while Capsules held 28.02% share with a 2.07% MoM drop and a 54.50% YoY contraction; Flower was 1.10% share with a 51.91% MoM fall and a 77.78% YoY decline. The brand’s average price eased 2.47% YoY to $31.51 as Concentrates averaged $32.11 and Capsules $29.53, indicating price stability where volume is accumulating; with Concentrates ranked 12th in Alberta, the mix is consolidating into a single growth outlet despite overall brand sales down 29.68% YoY. The pattern implies Stigma Grow is leaning into a defensive share strategy by reinforcing Concentrates to offset Capsule and Flower attrition, using modest price reductions to capture demand without undermining category positioning.
The pivot toward Concentrates, up 6.32% MoM while Capsules fell 2.07% MoM and overall brand sales declined 29.68% YoY, suggests a deliberate reallocation to higher-velocity formats that can improve efficiency at a 12th-place rank in Alberta and lower exposure to volatile sub-categories. With Capsules down 54.50% YoY and Flower down 77.78% YoY, and the brand’s average price down 2.47% YoY against a Concentrates average of $32.11, the pricing corridor supports a premium-leaning but accessible stance within extracts. The implication is that near-term positioning should emphasize depth in Concentrates and deprioritize low-share categories, using targeted pricing and assortment pruning to stabilize share and defend rank while rebuilding velocity.
Competitive Landscape
Stigma Grow sits at rank #12 in AB Concentrates in August 2026, improving 2 positions year over year from #14 and slipping 2 spots from May 2026’s #10, while its peak at #8 in April 2026 marks a 4-rank betterment versus current. Against competitors, BoxHot holds #1 both this year and last despite a -2.6% YoY sales change, and Dab Bods remains #3 with a 69.5% YoY sales increase, whereas Sticky Greens rose from #49 to #5 with a 1486.7% YoY surge; these moves indicate Stigma Grow’s modest rank gain is being outpaced by faster climbers. The pattern implies Stigma Grow’s trajectory—up 2 ranks YoY but down 2 ranks since May 2026—signals mid-pack stability that risks further dilution unless it counters rapid-share accretion from rising rivals.
Notable Products
Grape Limeade (14g) posted the steepest decline in August 2026 at -60.4% with a drop to rank 7, while Phoenix Tears Resin (1g) also fell -52.3% to rank 6; together these back-to-back declines contrast with Phoenix Tears Honey Oil (1g) rising 36.1% at rank 5, implying the brand is consolidating around concentrates rather than flower. Phoenix Tears RSO (1g) held rank 1 with +8.4% MoM and more than $113,000 in sales, as CBD Softgels 15-Pack (750mg CBD) climbed 47.7% to rank 3 while Indica RSO Capsules 25-Pack (250mg) slipped -6.7% at rank 2, and four of the top ten are Concentrates SKUs, indicating the product mix is tilting toward flagship RSO-led concentrates with selective capsule support over de-prioritized flower.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
